chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Felt flushed, body aching, nose begin to bleed, took about 30 minutes to stop the bleeding. Nose begin to bleed again at 12N, again took about 30 minutes to stop. Seen by phys at clinic, no labs or meds prescribed.
This case was reported by a healthcare professional and described the occurrence of acute hepatic failure in a 72-year-old male subject who was vaccinated with HAVRIX (GlaxoSmithKline). Concurrent vaccination included Salmonella typhi Vi capsular polysaccharide vaccine (manufacturer unspecified) and tetanus and diphtheria toxoids adsorbed (manufacturer unspecified) both given on 27 January 2012. On 27 January 2012 at 14:15 the subject received 1st dose of HAVRIX at 1 ml in the left arm as a travel vaccination. Three months after vaccination with HAVRIX, in April 2012, the subject experienced acute hepatic failure. Additional information received indicated that the subject had experienced liver failure following vaccination with HAVRIX: however, an onset date for the event was not provided. The event occurred within months of receiving the 1st dose of HAVRIX. This report was also associated with a product complaint as the reporter questioned if there was a problem with this lot (AHAVB493BA exp. 26 August 2013) of HAVRIX. This case was assessed as medically serious by GSK. At the time of reporting the outcome of the events was unspecified.
cytotoxic T-cell lymphoma; This is a literature report.  A 62-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: T-CELL LYMPHOMA (medically significant), outcome "unknown", described as "cytotoxic T-cell lymphoma". The patient underwent the following laboratory tests and procedures: Flow cytometry: slightly elevated CD4/CD8 ratio; Positron emission tomogram: mildly hypermetabolic, notes: non-enlarged bilateral axillary and pelvic lymph nodes.; Sender's Comments: Based on the available information and close temporal association, a possible causal relationship cannot be excluded between the suspect vaccine BNT162b2 and the reported event T-cell lymphoma. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
I did not have an adverse reaction to the vaccine. I started not feeling well on 04/29/2023 with chills and a dry cough. I was out of the country at this time. I came back home on 05/02/2023. I tested positive for COVID-19 on 05/03/2023. I contacted my doctor and got a prescription for Paxlovid. At this time, I am tolerating the medication without any complications.
Starting the day after the vaccine she had fatigue, fever, and a swollen and painful axillary lymph node on her left underam.
Swollen gland in axillary area of arm of injection; Tenderness under arm of injection/Area of injection is sore; This spontaneous case was reported by an other health care professional and describes the occurrence of LYMPHADENOPATHY (Swollen gland in axillary area of arm of injection) and VACCINATION SITE PAIN (Tenderness under arm of injection/Area of injection is sore) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.     On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, the patient experienced LYMPHADENOPATHY (Swollen gland in axillary area of arm of injection) and VACCINATION SITE PAIN (Tenderness under arm of injection/Area of injection is sore). At the time of the report, LYMPHADENOPATHY (Swollen gland in axillary area of arm of injection) and VACCINATION SITE PAIN (Tenderness under arm of injection/Area of injection is sore) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not reported. The patient not taking any treatment medication.  It was reported that on 16-Mar-2021, the Symptoms were persisted
My body has edema; My body has swelling/swelling in her body; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of GENERALISED OEDEMA (My body has edema), SWELLING (My body has swelling/swelling in her body) and VACCINATION SITE PAIN (Sore arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced GENERALISED OEDEMA (My body has edema), SWELLING (My body has swelling/swelling in her body) and VACCINATION SITE PAIN (Sore arm). At the time of the report, GENERALISED OEDEMA (My body has edema), SWELLING (My body has swelling/swelling in her body) and VACCINATION SITE PAIN (Sore arm) had not resolved.            The concomitant medications were not reported.  The treatment information was not provided.
Diagnosed with Shingles; Accidental overdose; This is a spontaneous report from a contactable consumer (patient). A 51-year-old non-pregnant non pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: ER2613), via an unspecified route of administration, administered in arm right on 25Mar2021 (at the age of 51-years-old) as dose 1, single and second dose (Batch/Lot Number: EW0158) via an unspecified route of administration, administered in Arm Right on 25Mar2021 as dose 2 single for covid-19 immunisation at the hospital. The patient had no medical history. The patient had no known allergies. The patient's concomitant medication included sertraline hydrochloride (ZOLOFT) taken for an unspecified indication and unspecified allergy medications and vitamins. The patient had no other vaccine in four weeks. No covid prior vaccination. The patient was not tested for covid post vaccination. On 25Mar2021, the patient experienced accidental overdose. On 10Jun2021, the patient was diagnosed with shingles. As a treatment for diagnosed with shingles the patient received valtrex, topical. The clinical outcome of the diagnosed with shingles was recovering and the outcome of the accidental overdose was unknown.
Within two weeks following second covid shot, my mother developed extreme pulmonary issues with lungs that presented a "ground glass" appearance. Shortly thereafter, she was diagnosed with interstitial lung disease despite having never been a smoker or exposed to asbestos.  While her medical doctor does not believe there is a connection, in the 8-10 weeks following the initial event she is improving significantly.  It took three hospital stays, a lung biopsy, a pulmonary embolism and lengthy time in the ICU but she is starting to improve to the point that she does not need oxygen. The level of improvement she is showing and the rate of improvement seems inconsistent with ILD.
Following Fluvirin PFS 2015-16 IM Injection, patient apparently had syncope episode, not witnessed. Patient fall heard in front of pharmacy. Patient helped to floor horizontal position. 911 called. Patient lost consciousness for a short period of time by had a pulse and was breathing. Patient's son present. Son stated "she does this", and asked for a candy bar. Son states pt borderline diabetic. Son insisted upon leaving before 911 responders arrived. Pt agreed with son to leave before 911 responders arrived. Pt appeared recovered, walked with assistance to car.
History of Present Illness:  Patient developed pleuritic chest pain two weeks after receiving his primary SPV, typhoid vaccination, and influenza vaccination and was admitted to Medical Center with a diagnosis of myopericarditis.  See table below. Primary Smallpox Vaccination (L arm) Influenza, Typhoid PPD  10 Oct 03 No problems on this date.  Reports he had received the briefing on smallpox vaccination. 18 Oct 03 While shooting at the 9mm range, he began experiencing a headache, ringing in his ears, and chest pain.  He described the chest pain as localized to his left side.  Rated it as a 5-6 on a 0 (no pain)  10 (worst pain ever) scale.  Took Advil with slight relief. After leaving the rifle range, his headache persisted but the chest pain had eased off.  He was able to fall asleep but was awakened from his sleep around 1 AM with chest pain.   19 Oct 03 Chest pain continued and at approximately 7:30 am, he was experiencing sharp, stabbing pain that had increased to a 7-8 on a pain scale.  Pain also radiated down his left arm.  Worse with inspiration.  Noted the pain even without exertion.  Experienced shortness of breath with the pain.  Also complained of a dry cough. Service member reports that he has had episodes of chest pain in the past but they were not similar to this chest pain.  Previously it was centered on the left side of his chest with no radiation.  At times, the pain could increase to a 5-6 on the pain scale.  No change with breathing or exertion.  No complaints of heartburn.  Has not been medically evaluated in the past for chest pain. Went to Medical Center Emergency Room and was admitted with a diagnosis of myocarditis.  EKG normal but cardiac enzymes elevated.  Initial CXR was normal. 20 Oct 03-23 Oct 03 Remained hospitalized at Medical Center.  Medications included aspirin 325 mg po QID, Morphine 2 mg prn pain, Percocet prn pain, Ibuprofen 800 mg q 8 hr, and Lovenox 100 mg q 12 hr.  He also had some temperature spikes while in the hospital.  Blood and urine cultures were negative.  He was placed on Tylenol 650 mg q 4-6 hours prn.  Through the course of hospital stay, patient's chest pain and headache resolved.  No further shortness of breath.  Follow-up CXR showed small left pleural effusion.  Echocardiogram showed LVEF =45-50%.  Cardiac enzymes decreased and patient was discharged home on 23 Oct 2003.  He was placed on a 6-month convalescent leave. 27 Oct 03 Follow-up conducted with patient at home.  No further complaints of chest pain or shortness of breath.  He was discharged on Motrin prn but has not needed it.  He has a follow-up appointment with the Hospital tomorrow. 60-day follow up 2/17/04:  He continues to experience occasional exertional chest pain approximately once every 3 days, along with some dyspnea on exertion. He is now due for his 6-12 month follow up. Once the evaluation is completed, I will file a follow up report.
Full-body rash with little bumps; extremely itchy. Began 10 days after flu vaccine. Has not resolved after 1 week. Taking prednisone to treat rash.
Nausea; Headache; Chills; Tiredness; Dose number: 3; This is a spontaneous report from a non-contactable reporter (consumer or other non-HCP). The reporter is the patient.  An adult female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 22Dec2021 (Lot number: FL3197) as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "None" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: EL3247; Route of Administration: Unspecified), administration date: 03Feb2021, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot Number: EL3247; Route of Administration: Unspecified), administration date: 24Feb2021, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 22Dec2021, outcome "unknown", described as "Dose number: 3"; NAUSEA (non-serious) with onset 23Dec2021 at 01:30, outcome "recovered" (23Dec2021), described as "Nausea"; HEADACHE (non-serious) with onset 23Dec2021 at 01:30, outcome "recovered" (23Dec2021), described as "Headache"; CHILLS (non-serious) with onset 23Dec2021 at 01:30, outcome "recovered" (23Dec2021), described as "Chills"; FATIGUE (non-serious) with onset 23Dec2021 at 01:30, outcome "recovered" (23Dec2021), described as "Tiredness". Therapeutic measures were taken as a result of nausea, headache, chills and fatigue.  Additional Information: Treatment for the events included IBUPROFEN. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.   No follow-up attempts are possible. No further information is expected.
Pt recv vax on 10/6/98; post vax pt exp rash on her left thigh
Most of left arm is swollen, red, warm to touch. Injection site is red and blotchy. Patient feels lethargic and mind feels foggy.
At 10:40 the same day, the pt developed an injection site reaction that included 3x3" erythema, which was painful to the touch and severe urticaria. The pt was given 3/4 tsp of Benadryl and was observed. The reaction was gone after 72 hours and the pt recovered. Follow up information received 10/31/2000 states no further information is anticipated for this report. The case is closed.
Cellulitis; Red patches; one lump but not bright red looks like pinkish color / three more lumps appeared; hot to the touch; painful; allergic reaction; hard at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of CELLULITIS (Cellulitis) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CELLULITIS (Cellulitis) (seriousness criterion medically significant), ERYTHEMA (Red patches), MASS (one lump but not bright red looks like pinkish color / three more lumps appeared), SKIN WARM (hot to the touch), PAIN (painful), HYPERSENSITIVITY (allergic reaction) and VACCINATION SITE INDURATION (hard at the injection site). At the time of the report, CELLULITIS (Cellulitis), ERYTHEMA (Red patches), MASS (one lump but not bright red looks like pinkish color / three more lumps appeared), SKIN WARM (hot to the touch), PAIN (painful), HYPERSENSITIVITY (allergic reaction) and VACCINATION SITE INDURATION (hard at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Treatment medication included antibiotics.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
02/03/2016 - 02/05/2016 Mild fever (less than 101). 02/05/2016 - developed a spotted, raised rash. 02/06/2016 - spotted, raised rash more pronounced.
ATRIAL FIBRILLATION.  SENT OT HOSPITAL ON 03/08 AND WAS CARDIOVERTED ON 03/10.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On an unknown date the patient was vaccinated with VARIVAX (lot# and expiration date not provided) (dose not reported). On an unknown date the patient received dose of VARIVAX that was exposed to temperature above the recommended temperature range. No adverse effect was reported. This is one of several reports from the same reporter (Same Reporter Link: MARRS#1405USA014687, MARRS#1405USA015420, MARRS#1405USA015421, MARRS#1405USA015422). Additional information has been requested.
Patient reported a mild grade fever of 100.7, arm soreness and headache over the course of 3 days. Resolved itself after 3 days.
Chest pain radiating down left arm, RUQ abd pain, fever, moderate to severe muscle cramps,  joint pain, diarrhea
Starting 2/ 20, I woke up with 2 connected puffy red patches on my arm just below the vaccine site. I could tell it was below since I still had the bruise from the vaccine. Over the next few days, the spot on my arm continued to grow and spread. It has a darker red ring on the edges. It is currently about 2.5"x5" in size today (2/24). It started out about 2.5"x1" on 2/20. It has not faded yet.
Left upper shoulder swelling, induration, redness; able to move arm. Ice to arm 4-5 times a day. Tylenol PRN. Call for fever/decreased range of motion.
Immediately have ringing in ears.  Bouts of confusion if too many people are talking in a room voices become muffled. I have lost my concentration. I'm a programmer I'm praying I get it back or I will loose my job... Also erratic mood swings.   I received the second shot 4/9/2021 and still have these simptoms.
multiple sclerosis; serious neurological issues; issues with left leg; numbness on left side; depression; constant pain; fatigue; anxiety; This initial spontaneous report was received from a lawyer regarding a case in litigation referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions or concomitant medications were not reported. In or about 30-OCT-2015, the patient was administered zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dosage, route of administration and anatomical location were not provided) for the long-term prevention of shingles and zoster-related conditions by a healthcare provider. Subsequently, on an unknown date, the pt was treated by unspecified providers, for the following injuries resulting from the pt's use of zoster vaccine live (ZOSTAVAX): serious neurological issues, issues with left leg, fatigue, constant pain and numbness on left side, depression, anxiety and multiple sclerosis. The outcome of the events was not reported. The reporter considered all events to be related to Zoster Vaccine Live (ZOSTAVAX).  Upon internal review, the event of multiple sclerosis was determined to be medically significant. The event of nervous system disorder was considered serious by the reporter.
Ear infection-Right ear Diagnosed 12/30  (treated with 10 day course of Augmentin), pain in ear and jaw continue despite antibiotics, jaw pain, ear fullness, with decreased hearing.
crying, paleness, cyanosis of lips, lethargic, cold to touch x 20 mins;
12/21/2021 10 PM my Covid symptoms started with runny nose. I didn't think anything of it but I woke up at 10 PM and felt achy. I bought a home test and it was positive, and by morning I have a severely sore throat, and to me the worst symptom was the sore throat. The sore throat lasted 3 days but it was odd because my tonsils weren't swollen and it was lymphoid hyperplasia. My posterior pharynx had severe lymphoid hyperplasia and it looked like ulcers, but my tonsils weren't swollen. I also had a mild dry cough and it was sporadic and didn't keep me up at night. I had chills without fever where I was freezing cold as well as tiredness and fatigue and that lasted 24 hours.
Information has been received from a health professional concerning an approximately 10 year old female who on 25-MAR-1997 was vaccinated with a dose of Varivax. Subsequently, the patient experienced a generalized rash with 50-200 lesions. It was unknown if there was a cough or fever. This case was documented or evaluated by a physician. The child was not hospitalized. No additional information was provided. Additional information has been requested.
patient rec'd grey cap pfizer vaccine after it was stored in freezer for 22 days- replacement dose rec'd 6/2/22
Redness, pain and swelling at injection site, noticed the day following immunization, 11/09/05.
Patient presented to the ER for chief complaint of fatigue, diarrhea, and dyspnea. Patient was seen by his PCP and referred to the EC for further evaluation.  Symptoms started a few days prior to presentation.  Patient had positive contact with his wife with COVID-19.   Chest x-ray shows right mid lower lung infiltrate. Patient was found to be positive for COVID-19. He was hypoxic and was started on supplemental O2 and Decadron. While admitted, patient developed atrial flutter with rapid response. Cardiology was consulted and patient has been started on diltiazem. His HR improved as did his respiratory status and he was able to be weaned to room air. Decadron was discontinued as he was no longer hypoxic and he was discharged home.
Initial report received from a health care professional on 11 November 2009. This report involved a case of misuse where the patient received two pediatric doses of FLUZONE combined into one injection. A 35-year-old female patient with a history of asthma, fibromyalgia and known allergies to penicillin, sulfa and latex and who was breastfeeding mother at the time of vaccination, had received an intramuscular right deltoid injection of FLUZONE, lot number U3262HA on 10 November 2009 at 11:30 am and five minutes later, she developed injection site swelling and cold hands. Benadryl was administered and the patient was sent home. At 3:00 pm, the patient went to emergency room with complaints of hives, malaise, fatigue, headache and fever of 102F and was released. At 3:00 am, the patient returned to the emergency room with the same symptoms in addition to left breast pain. The patient was diagnosed with mastitis. The patient had no concurrent illness and she had not been taking any concomitant medications at the time of vaccination. She had no adverse events following prior vaccinations. At the time of the report, the patient's recovery status was unknown. Documents held by sender: None.
The morning of October 31st the day after my shot at 9:30 am I breathed in and my upper back on the left side hurt so bad I screamed. I received my booster on my left arm. It hurt behind my left breast as well when I breathe in and today is Tuesday November  2nd. Vaccine site is still a bit sore.
On March 23, 2021 I began to have a distorted sense of taste and smell.  Everything smells like very rotten meat and everything tastes how it smells.  I have been unable to eat meat protein, nut protein, protein shakes and most other proteins (the only protein I am able to eat is cheese)  since that day, it has only been within the last week that I have been able to eat cooked sea bass and raw salmon. Protein is not the only thing I am having issues with, and toasted, cooked or warm food is inedible. I also tested positive for Covid-19 on March  25, 2021 (after I received both pfizer vaccines)
Approximately 24 hours after vaccine noticed unusual pain and swelling, redness and warmth at site. Went to walk-in-care: prednisone injection and PO x 3 days. Due to history of cellulitis 24 hrs prior to a flu shot, recommend allergy testing.
RIGHT THIGH SWOLLEN FROM HIP TO KNEE, WITH INVOLVEMENT OF KNEE JOINT INFRAPATELLAR ONLY.  FULL RANGE OF MOTINO.  NO REDNESS, RASH, OR WARMTH.  LIMPING HEAVILY WHILE FAVORING RIGHT LEG.  SLIGHT TENDERNESS SUPERIOR TO PATELLA AND AT RIGHT HIP JOINT.  NO FEVER.  BILATERAL OTITIS MEDIA ON EXAM
pt recv vax 22JAN98 & approx 24JAN98 48hr post vax pt exp swelling from the inj site to fingers & the area was sore & red, hot to touch;